Mylan controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile7 entries
2021
Mylan sues Teva over alleged Copaxone competition restraints
Lawsuit filed
Mylan Pharmaceuticals filed a federal lawsuit against Teva, alleging that Teva used tactics to delay competition for its multiple sclerosis drug Copaxone. The allegations are presented as claims in the filing rather than as a court determination, and Teva had not yet responded at the time of the report.
Source excerpt
With the suit just filed, Teva has not yet had time to file a response.
Mylan alleges that Teva used various tactics to delay competition and maintain its monopoly on Copaxone, costing the U.S. healthcare system billions in excess spending.
Morgantown-based Mylan Pharmaceuticals—not its parent Viatris—filed the suit in U.S. District Court for the District of New Jersey against Teva and several of its subsidiaries.
2021
Kansas court rules substantially in Mylan's favor in EpiPen class action
Ruling
The U.S. District Court for the District of Kansas ruled substantially in Mylan's favor on its summary judgment motion in a class action related to the EpiPen Auto-Injector. The court dismissed the plaintiffs' federal RICO claims and claims alleging that Mylan foreclosed branded competition through rebate arrangements. The court did not decide the remaining claim on its merits.
Source excerpt
Viatris (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the company's summary judgment motion in the class action related to EpiPen® Auto-Injector.
The company is pleased with the court's decision to dismiss all of the plaintiffs' claims under the federal RICO statute, which include claims asserted against Mylan's former CEO Heather Bresch. The court also dismissed claims alleging that Mylan foreclosed branded competition through rebate arrangements with pharmacy benefit managers.
The only remaining claim in this class action pertains to a patent settlement between Pfizer and Teva and other alleged actions regarding the launch of Teva's generic epinephrine auto-injector. Today's ruling was not a decision on the merits of that claim
2020
Court enters summary judgment in Mylan's favor in Sanofi lawsuit
Ruling
The U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought by Sanofi over EpiPen products. Viatris characterized the court action as rejecting Sanofi's allegations of anticompetitive practices; the source reports a judgment, not a separate finding of misconduct.
Source excerpt
Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen® products.
it rejects Sanofi's baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen
2016
EpiPen pricing controversy
Mylan faced widespread criticism and investigations over increases in the price of EpiPen, along with questions about competition, rebates, contracting practices, and access to emergency epinephrine.
2013
Manufacturing-quality scrutiny after Agila acquisition
Several Mylan facilities, including sites acquired through Agila, received regulatory criticism over contamination and manufacturing-compliance issues, prompting questions about integration and quality control.
2009
Medicaid rebate allegations
Mylan and UDL agreed to pay to resolve allegations that certain medicines had been treated as generics for Medicaid rebate purposes even though the government claimed they should have received higher rebate treatment.
1998
Generic-drug pricing and supply investigation
The FTC and numerous states challenged price increases for lorazepam and related medicines following an exclusive active-ingredient supply arrangement. The matter was resolved in 2000 through payments and an injunction addressing similar anticompetitive conduct.